Acute Adverse Effects of IV Epinephrine Push in Newborns
The most critical adverse effect of IV epinephrine in newborns is increased mortality risk and impaired cerebral blood flow when doses exceed 0.03 mg/kg, with additional concerns about post-resuscitation hemodynamic instability and potential neurological injury. 1, 2
Documented Adverse Effects
High-Dose Toxicity (Most Critical)
- Intravenous epinephrine doses ≥0.1 mg/kg significantly increase post-resuscitation mortality risk without improving survival to hospital discharge 3, 1
- High-dose IV epinephrine (≥0.1 mg/kg) interferes with cerebral cortical blood flow and cardiac output in pediatric animal studies 3, 1
- Planned secondary analysis of pediatric trials suggests increased mortality risk among children receiving high-dose IV epinephrine (0.1 mg/kg) 3, 1
Hemodynamic Effects
- Negative hemodynamic effects have been observed, particularly with doses ≥30 μg/kg (0.03 mg/kg) administered intravenously 4
- The vasoconstriction mechanism that increases coronary perfusion pressure can paradoxically impair peripheral and cerebral perfusion when excessive 5
Neurological Concerns
- Potential impairment of neurological outcomes, especially in birth asphyxia and preterm infants, though causality remains unestablished from retrospective studies 4
- The 2020 International Consensus identifies neurodevelopmental outcomes after epinephrine use as a critical knowledge gap requiring monitoring 6
Route-Specific Complications
IV/Umbilical Venous Route
- Extravasation is listed as an important morbidity when IV administration occurs 6
- Embolic phenomenon and phlebitis are recognized complications of IV epinephrine administration 6
Endotracheal Route (for comparison)
- Results in unpredictable absorption and lower plasma concentrations, requiring higher doses (0.05-0.1 mg/kg) 6, 7
- Less effective than IV route but carries lower risk of the severe adverse effects seen with high-dose IV administration 6
Critical Safety Parameters
Recommended Safe Dosing
- The safe IV dose range is strictly 0.01-0.03 mg/kg (10-30 mcg/kg) 6, 8
- Doses above 0.03 mg/kg IV cannot be recommended and may be harmful 3, 1
- Repeat doses should maintain this same range every 3-5 minutes if heart rate remains <60 bpm 6, 9
Population-Specific Vulnerabilities
- Preterm infants may have impaired hemodynamics and neurological outcomes with epinephrine, though evidence is limited 4
- Birth asphyxia cases may experience worse outcomes with epinephrine administration, but causal relationships cannot be definitively established 4
Monitoring Requirements
Immediate Post-Administration
The 2020 International Consensus recommends health services monitor: 6
- Infant characteristics and gestational age
- Resuscitation measures received before epinephrine
- Exact doses, routes, and treatment intervals used
- Any adverse effects of treatment (specifically mandated for documentation)
Critical Outcomes to Track
- Death during event, within 24 hours, and before hospital discharge 6
- Brain injury including HIE Stage 2-3 (term infants) and intraventricular hemorrhage Grades 3-4 (preterm infants) 6
- Time to return of spontaneous circulation 6
Common Pitfalls to Avoid
Dosing Errors
- Never administer high-dose IV epinephrine (>0.03 mg/kg) thinking it will improve outcomes—it increases mortality without benefit 3, 1, 2
- Do not confuse endotracheal dosing (0.05-0.1 mg/kg) with IV dosing (0.01-0.03 mg/kg) 6, 7
Timing Issues
- Avoid premature epinephrine administration before establishing adequate ventilation and chest compressions 2
- Do not delay repeat doses beyond 5 minutes if heart rate remains <60 bpm 9
Administration Technique
- Ensure proper umbilical venous catheter placement to avoid extravasation 6
- Administer as rapid IV push, not slow infusion, during cardiac arrest 6
Knowledge Gaps Requiring Caution
The 2020 International Consensus explicitly identifies that potential harms of epinephrine (single or multiple doses) remain inadequately studied 6. This uncertainty, combined with documented risks at higher doses, mandates strict adherence to recommended dosing parameters and careful post-resuscitation monitoring for adverse effects.